Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O75112

UPID:
LDB3_HUMAN

ALTERNATIVE NAMES:
Protein cypher; Z-band alternatively spliced PDZ-motif protein

ALTERNATIVE UPACC:
O75112; A2TDB7; A6NIV4; B4E3K3; Q5K6N9; Q5K6P0; Q5K6P1; Q96FH2; Q9Y4Z3; Q9Y4Z4; Q9Y4Z5

BACKGROUND:
The protein known as LIM domain-binding protein 3, with alternative names Protein cypher and Z-band alternatively spliced PDZ-motif protein, is pivotal in connecting protein kinase C-mediated signals to the cytoskeleton in striated muscles via its LIM domains. This essential function indicates its role in muscle physiology and disease.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of LIM domain-binding protein 3 could open doors to potential therapeutic strategies. Its direct involvement in diseases such as Cardiomyopathy, dilated, 1C, Left ventricular non-compaction 3, and Myopathy, myofibrillar, 4, positions it as a significant target for developing treatments aimed at improving muscle function and cardiovascular health.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.